Arca
Skip to content

Hepatitis c virus genotype 3

Drug research and approvals for hepatitis c virus genotype 3: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 0 studies of hepatitis c virus genotype 3 are recruiting on ClinicalTrials.gov, and Health Canada has authorized 8 drug trials for it since 2013.

  • Recruiting worldwide: 0
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 0
  • EU medicines: 0

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jul 20, 2017A phase 3 clinical study to evaluate the efficacy and safety of the combination regimen of mk-3682b (grazoprevir/ruzasvir/uprifosbuvir) in participants with…MK-3682B [GRAZOPREVIR (MK-5172)-RUZASVIR (MK-8408)-UPRIFOSBUVIR (MK-3682)]Merck & Co. (MSD)Pending
Feb 18, 2016A phase 3 evaluation of daclatasvir and sofosbuvir with ribavirin in cirrhotic subjects with genotype 3 chronic hepatitis c infectionDACLATASVIR (BMS-790052)Bristol-Myers SquibbClosed
Oct 20, 2015A randomized, open-label study of daclatasvir and sofosbuvir with or without ribavirin for 8 weeks in treatment-naive, non-cirrhotic subjects infected with…DACLATASVIR (BMS-790052)/ SOFOSBUVIR/ RIBAVIRINBristol-Myers SquibbPending
Oct 7, 2015A randomized, open-label, active-controlled, multicenter study to compare efficacy and safety of abt-493/abt-530 to sofosbuvir co-administered with daclatasvir…ABT-493-ABT-530/ SOFOSBUVIR/ DACLATASVIRAbbVieClosed
Feb 6, 2015A phase 2 open- label study to evaluate the safety and efficacy of ledipasvir/sofosbuvir (ldv/sof) fixed dose combination tablet with ribavirin for 12 weeks in…SOFOSBUVIR-LEDIPASVIR/ RIBAVIRINGilead SciencesClosed
Dec 18, 2014A phase II, randomized, open-label clinical trial to study the efficacy and safety of the combination regimen of mk-5172 and mk-3682 with either mk-8742 or…MK-3682/ MK-5172/ MK-8742/ MK-8408Merck & Co. (MSD)Closed
Oct 15, 2014A randomized, open-label study to evaluate the safety and efficacy of the co-administration of ombitasvir/abt-450/ritonavir (ombitasvir/abt-450/r) with…PARITAPREVIR (ABT-450)-RITONAVIR-OMBITASVIR (ABT-267)/ SOFOSBUVIR/ RIBAVIRINAbbVieClosed
Jul 23, 2014A multicenter, open-label, partially randomized, parallel-group, adaptive design, phase II study on efficacy and safety of deb025/alisporivir in combination…ALISPORIVIR (DEB025)/ MERICITABINE (RO5024048)/ RIBAVIRINNovartis Pharmaceuticals CorporationPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.